Research Progress on Immunization and Targeted Therapy for Triple-negative Breast Cancer
10.3971/j.issn.1000-8578.2023.22.1426
- VernacularTitle:三阴性乳腺癌免疫及靶向治疗研究进展
- Author:
Chao SHI
1
;
Xiangmei ZHANG
;
Yunjiang LIU
Author Information
1. Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
- Publication Type:Research Article
- Keywords:
Triple-negative breast cancer;
Immunotherapy;
Targeted therapy;
LAG3
- From:
Cancer Research on Prevention and Treatment
2023;50(7):710-716
- CountryChina
- Language:Chinese
-
Abstract:
Triple-negative breast cancer (TNBC) accounts for approximately 15%–20% of all breast cancers. Patients with TNBC have a rapidly progressive clinical course, an earlier age of onset, faster distant recurrence, and more common visceral metastases as compared with other subtypes. However, treatment of TNBC is often limited to chemotherapy and has a poor prognosis. Therefore, developing the best treatment strategy for patients is essential to reduce the burden of disease caused by TNBC. Various potential available drug targets have been discovered, as well as precision treatment and classified treatment are changing the clinical practice of TNBC, thereby indicating a new therapeutic area for TNBC in addition to traditional chemotherapy. This article reviews the systemic treatment options for TNBC in recent years, including immunotherapy and targeted therapy.
